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Enterobacteriaceae are a large group of Gram-negative, rod-shaped 
bacteria. They are the bacteria most frequently isolated from clinical 
specimens and may account for up to 80% of all clinically signifi cant 
isolates from Gram-negative bacilli and up to 50% of all clinically 
significant bacteria.[1] Enterobacteriaceae cause both nosocomial 
and community-acquired infections and are increasingly becoming 
multidrug resistant (MDR) to antimicrobial agents. The past few 
decades have seen the rapid emergence and spread of antimicrobial 
resistance, with clinicians having to rely on the carbapenem 
class of antibiotics to treat these resistant organisms. [2] However, 
increasing rates of carbapenem resistance are being reported.[3] The 
mechanism of resistance to carbapenems among Enterobacteriaceae 
is complex and mediated by several different mechanisms, such as 
the over-production of ampC enzymes, extended-spectrum beta-
lactamases (ESBLs), carbapenemases that inactivate the β-lactam 
antibiotics, including the carbapenems, efflux pumps and deletion 
of porins.[3-5] There are several classes of carbapenemase-produ-
cing Enterobacteriaceae (CPE), which include non-metalloenzymes 
(Klebsiella pneumoniae carbapenemases (KPC), Guiana extended-
spectrum β-lactamases (GES), oxacillinase-type carbapenemases 
(OXA-48) and their derivatives) and metallo-β-lactamases (MBL) 
(imipenemases (IMP), Verona integron-encoded MBL (VIM) and 
New Delhi metallo-β-lactamase (NDM-1/2)). CPE are associated 
with increased morbidity and mortality as a result of limited 
treatment options rather than the expression of specific virulence 
characteristics.[6,7] CPE also have the potential for widespread 
transmission of carbapenem resistance owing to easily transmissible 
resistance genes on plasmids and chromosomes.[6,7] The focus given to 
carba penemase detection despite all other mechanisms of resistance 
was due to the availability of molecular test methods.
Among all CPE, the most common enzyme was NDM-1.[3] 
NDM-1 was first described in 2008 in a Swedish patient returning 
from New Delhi, India,[8] in both Escherichia coli and K. pneumoniae 
isolates, which carried the novel MBL gene (blaNDM-1).[9] NDM-1 has 
subsequently been reported worldwide, with most early cases of 
NDM-1 diagnosed in the UK having epidemiological links with the 
Indian subcontinent.[8]
Objective
To demonstrate the presence of carbapenemases in Enterobacteri-
aceae over a 4-year period, based on a referral system for confirmation 
of CPE genes.
Methods
Carbapenem non-susceptible, clinically significant isolates from 
the Enterobacteriaceae family were submitted to the Antimicrobial 
Resistance Laboratory (AMRL) at the National Institute for 
Communicable Diseases (NICD), Johannesburg, South Africa (SA), 
for confirmation of carbapenemase-producing genes from 2012 
through 2015. Referral of isolates by public and private microbiology 
laboratories was based on non-susceptibility to carbapenems by 
disc diffusion (Kirby-Bauer method, using Oxoid Antimicrobial 
Susceptibility Test Discs (Oxoid, UK)) or minimal inhibitory 
concentration (MIC) testing methods interpreted by the Clinical 
and Laboratory Standards Institute guideline.[10] Submission practice 
from public laboratories was based on a guideline from the reference 
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laboratory at the NICD and from private 
laboratories on a voluntary basis.
Organism identification was reconfirmed 
using automated systems (VITEK 2 (bio-
Mèrieux, France) and/or Matrix-Assisted 
Laser Desorption Ionization-Time of Flight 
Mass Spectrometry (MALDI-ToF, Bruker 
Daltonik GmbH, Germany), and anti-
microbial susceptibility testing (AST) was 
done using the MicroScan Walkaway system 
(Siemens, USA) at the AMRL. For molecular 
methods, DNA was extracted from purity 
plates using a crude boiling method at 
95oC for 25 minutes. The supernatant was 
harvested and screened for blaNDM, blaKPC, 
blaOXA-48 and its variants, blaGES, blaIMP and 
blaVIM, using a real-time polymerase chain 
reaction (LightCycler 480 II, Roche Applied 
Science, Germany), the LightCycler 480 
Probes Master kit (Roche Diagnostics, 
USA) and individual LightMix Modular 
kits (Roche Diagnostics, USA). Kit-positive 
controls as well as in-house controls were 
used in all assays (blaNDM, ATCC BAA21246; 
blaKPC, ATCC BAA1705; blaOXA-48 and its 
variants, NCTC13442; blaGES, clinical isolate; 
blaIMP, NCTC 13476; and blaVIM, clinical 
isolate). Sterile water was used as a negative 
control.
Statistical analysis
Where appropriate, we calculated frequencies 
and percentages and used the χ2 test/Fisher’s 
exact test to compare categorical variables. 
Statistical analyses were performed using 
STATA 14 (StataCorp, USA).
Ethical considerations
Laboratory-based antimicrobial resistance 
surveillance for nosocomial bacteria was 
approved by the Human Research Ethics 
Committee (Medical) at the University of 
the Witwatersrand, Johannesburg (clearance 
certificate no. M10464).
Results
We analysed 1 503 clinically significant 
Entero bacteriaceae isolates received for 
carbapenemase-producing gene confir-
mation. The age distribution of patients with 
carbapenem-resistant Enterobacteriaceae 
(CRE) infections showed two significant 
peaks, in children aged 0 - 5 years and 
in adults aged 30 - 40 years (p=0.05). 
Blood was the most common specimen 
type (25%), followed by urine (22%). We 
confirmed ESBL in 93% of isolates by the 
automated MIC method. Furthermore, 
carbapenemase-producing genes were 
con firmed molecularly in 68% of isolates 
(1 021/1 503). Of all Enterobacteriaceae, the 
most common was K. pneumoniae (60%), 
fol lowed by Enterobacter cloacae (14%) and 
Serratia marcescens (6%).
The most common carbapenemase-pro-
du cing genes were blaNDM, followed by blaOXA-48 
(Fig. 1). Carbapenemases were con firmed 
in 672 K. pneumoniae isolates (68%), and 
blaNDM was the most common gene identified 
(58%).
Of the blaNDM-positive isolates, 0.8% and 
0.6% showed susceptibility to ertapenem 
and ceftazidime, respectively. BlaOXA-48 and 
its derivatives demonstrated susceptibility 
to ertapenem in 11% of isolates and to 
ceftazidime in 66%.
The detection rate of carbapenemases 
among all K. pneumoniae blood isolates 
from public laboratories during the 4-year 
period was 1.9%. Based on voluntary 
referral practice, we could not estimate 
the preva lence of carbapenemases for all 
Enterobacteriaceae isolates and specimen 
types in SA.
Discussion 
This short report describes emerging 
resistance to carbapenems in Entero bacteri-
acae over a 4-year period in SA. We detected 
the presence of major carba penemases, i.e. 
NDM, OXA-48 and VIM. In a previous 
laboratory-based anti microbial resistance 
surveillance study conducted in 2010 - 2012, 
no isolates containing blaNDM or blaKPC were 
found, and blaGES and blaVIM were confirmed 
in <0.1%.[11] The present report suggests 
rapid dissemination of these genes once they 
are introduced into the environment, and we 
describe its longitudinal nature, which is in 
line with the global dissemination.[12]
The vast majority of the referral isolates 
produced ESBL, which is to be expected 
owing to the MDR patterns of these 
organ isms and compares with a previous 
surveillance report.[11] Enterobacteriaceae 
extensively exhibit MDR patterns, which 
enable them to persist and spread rapidly in 
healthcare settings.[13]
Our results indicate that blaOXA-48-positive 
isolates could be missed in 11% of isolates 
owing to susceptibility to ertapenem, yet 
43% were sensitive to imipenem and 57% 
to meropenem, which demonstrated that 
AST methods cannot be used for screening 
of these enzymes. This differs from an 
Indian study that showed 75% sensitivity to 
ertapenem and 84% sensitivity to imipenem 
and meropenem.[14] Poirel et al.[15] pointed 
out menace behaviour of these enzymes and 
the difficulties this poses for phenotypic 
detection. As we report here, some of these 
enzymes will be overlooked, particularly if 
carbapenems are used as indicators for AST 
resistance screening.
There are various approaches to the 
control of MDR organisms. Carmeli et 
al.[16] indicated that the objective for control 
should be eradi cation, while others such as 
Thurlow et al.[17] considered that a wider 
approach is needed once endemicity is 
established. Thurlow et al.[17] also suggested 
that reducing the burden of CPE on patients’ 
skin should be explored further as a way of 
reducing cross-transmission at long-term 
healthcare hospitals, where endemicity is 
most likely. Clinicians and infection control 
practitioners should be aware of the presence 
of carbapenemases in Enterobacteriaceae 
and its implications for infection prevention 
and control in the SA setting.
Study limitations
This report has a number of limitations. 
Owing to lack of policies and voluntary 
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Fig. 1. Carbapenemase-producing genes detected in 1 021 Enterobacteriaceae isolates referred to the 
AMRL at the NICD, 2012 - 2015.
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practice in sending isolates for confirmation to the reference 
laboratory, we were unable to determine the national prevalence 
of CPE or to establish whether there has been an increase in 
CPE in SA. Changes in submission practices and/or increased 
awareness of CPE infections undoubtedly influenced the number 
of isolates referred to the reference laboratory. However, this 
analysis reports a minimum estimate of the presence of CPE 
organisms and carbapenemase-producing genes in the country. 
Missing demographic, epidemiological and clinical data reduced 
our ability to analyse laboratory data in more meaningful ways. 
Surveillance for CPE through the Group for Enteric, Respiratory 
and Meningeal Disease Surveillance in South Africa (GERMS-SA) 
surveillance platform was introduced at 12 sentinel sites in four 
SA provinces in 2015. Future analysis of surveillance data for CPE 
should provide a more representative estimate of their prevalence 
and distribution in SA.
Conclusions
This report indicates the presence of CPE in SA. It is essential for 
all clinicians to be aware of this major public threat and be prepared 
to act if CPE occurs in patients. At all healthcare facilities, the 
importance of enforcing infection prevention and control measures 
to prevent the spread of CPE should be emphasised. Importantly, 
antimicrobial stewardship programmes should be implemented at 
facility level to prevent selection pressure on bacterial organisms to 
develop resistance.
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